Objective: An increased prevalence of thyroid autoimmunity has been observed after successful treatment of Cushing's syndrome. On the other hand, De Quervain's thyroiditis (DQT), in which autoimmunity is not a pathogenetic contributor, has not been reported during recovery from Cushing's syndrome. We describe 2 female patients with DQT coinciding with the resolution of hypercortisolism after treatment of Cushing's syndrome/disease. Methods: The first patient had been diagnosed with Cushing's disease due to a corticotroph pituitary microadenoma, declined neurosurgery, and was receiving pharmacological treatment with pasireotide. Her hypercortisolism was optimally controlled with a minimum dose. The second patient had undergone unilateral adrenalectomy due to a cortisol-secreting adenoma and was on tapering doses of hydrocortisone due to a suppressed corticotroph axis. Both patients presented with clinical, functional, and imaging features of DQT at a time when their endogenous glucocorticoid levels were very low. Results: Oral glucocorticoid treatment was administered in both cases, resulting in prompt recovery. Conclusions: The incidence of DQT following the resolution of hypercortisolism, either medical or surgical, has not been previously described. The exact pathogenetic mechanism can only be speculated on. Perhaps the relative or absolute glucocorticoid deficiency after effective treatment of hypercortisolism alters immunologic responses and renders patients more vulnerable to thyrolytic processes.

Keywords:
De Quervain’s thyroiditis, Cushing’s disease, Cortisol-secreting adrenal adenoma, Pasireotide, Endogenous hypercortisolism, Glucocorticoid withdrawal syndrome
1.
Colao A, Pivonello R, Faggiano A Filippella M, Ferone D, Di Somma C, Cerbone G, Marzullo P, Fenzi G, Lombardi G: Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clin Endocrinol 2000;53:13.
2.
Takasu N, Komiya I, Nagasawa Y, Asawa T, Yamada T: Exacerbation of autoimmune thyroid dysfunction after unilateral adrenalectomy in patients with Cushing's syndrome due to an adrenocortical adenoma. N Engl J Med 1990;332:1708.
3.
Kimura H, Sato K, Nishimaki M, Miki N, Ono M, Takano K: Symptomatic hypercalcemia due to painless thyroiditis after unilateral adrenalectomy in a patient with Cushing's syndrome. Inter Med 2008;47:751-756.
4.
Bateman A, Singh A, Kral T, Solomon S: The immune-hypothalamic-pituitary-adrenal axis. Endocr Rev 1989;10:92-112.
5.
Da Mota F, Murray C, Ezzat S: Overt immune dysfunction after Cushing's syndrome remission: a consecutive case series and review of the literature. J Clin Endocrinol Metab 2011;96:E1670-E1674.
6.
Desailloud R, Hober D: Viruses and thyroiditis: an update. Virol J 2009;6:5.
7.
Cribier B, Caille A, Heid E, Grosshans E: Erythema nodosum and associated diseases: a study of 129 cases. Int J Dermatol 1998;37:667.
8.
Elenkov IJ: Glucocorticoids and the Th1/Th2 balance. Ann N Y Acad Sci 2004;1024:138-146.
9.
Stojic-Vukanic Z, Rauski A, Kosec D, Radojevic K, Pilipovic I, Leposavic G: Dysregulation of T-cell development in adrenal glucocorticoid-deprived rats. Exp Biol Med 2009;234:1067-1074.
© 2014 European Thyroid Association Published by S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.